Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LU7K
|
|||
| Drug Name |
Pyrazolo[1,5-a]pyrimidine derivative 6
|
|||
| Synonyms |
PMID26161824-Compound-136
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Patented | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H21Cl2N5O5S2
|
|||
| Canonical SMILES |
CNS(=O)(=O)C1=NN2C(=C(C=NC2=C1C(=O)NC3CCS(=O)(=O)C3)C4=CC=CC=C4Cl)C5=CC=C(C=C5)Cl
|
|||
| InChI |
1S/C24H21Cl2N5O5S2/c1-27-38(35,36)24-20(23(32)29-16-10-11-37(33,34)13-16)22-28-12-18(17-4-2-3-5-19(17)26)21(31(22)30-24)14-6-8-15(25)9-7-14/h2-9,12,16,27H,10-11,13H2,1H3,(H,29,32)
|
|||
| InChIKey |
OGXPEWYKDODYIH-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Cannabinoid receptor 1 (CB1) | Target's Patent Info | [1] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.